Laurus Labs Share Price Surges 23% in a Month as CDMO Growth, Strong FY25 Drive Stock Higher

Laurus Labs share price climbed to an all-time high of ₹754.15 on July 2, 2025, rising 1% in intraday trade even as the broader market remained weak. The stock has been gaining for 9 consecutive sessions, up 17% since June 19. Over the past month, Laurus soared 23%, far outpacing the Sensex’s 2.7% gain. From its 52-week low of ₹390.30 in August 2024, the stock has surged 93%.

Laurus Labs FY25 Performance

After 3 years of slow earnings, Laurus posted a strong FY25, with profit more than doubling. This rebound was driven by:

• Better use of assets due to strong project execution in its CDMO (Contract Development and Manufacturing Organisation) segment
• New launches in the Finished Dosage Forms (FDF) business

Management expects consistent growth in the coming years. They plan to:

• Keep expanding CDMO capacity worldwide
• Invest in advanced services like biologics and gene therapy
• Leverage automation and AI to improve efficiency

Robust Manufacturing and R&D Footprint

Laurus operates 11 manufacturing sites (9 in Vizag and 2 in Bangalore) and 2 R&D centres. 6 plants are USFDA-approved, and some are certified by other international regulators. The company’s assets include:

• 8 API manufacturing units
• 1 FDF facility
• 7 CDMO units
• 2 bio-ingredient facilities

Read More: Key Financial Changes from July 2025: Aadhaar-PAN Linking, Taxes, Railways, HDFC Credit Cards, and More!

About Laurus Labs

Laurus Labs is a multinational pharma and biotech company based in Hyderabad, India. Founded in 2005 by Satyanarayana Chava, the company works across several areas, including active pharmaceutical ingredients (APIs), generic medicines, custom synthesis, biotechnology, veterinary APIs, and agrochemicals.

Conclusion

Laurus Labs has turned a corner with its strong FY25 results, improved capacity use, and growth in the high-margin CDMO segment. Its focus on innovation and diversification is attracting investors. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in securities are subject to market risks. Read all related documents carefully before investing.